Indaptus Therapeutics

R&D

Interview at BIO 2025 with Jeffrey Meckler

Going wide on immune system activation, with Jeffrey Meckler

Indaptus CEO Jeff Meckler discusses his company's unconventional approach to immunotherapy, based on activating a wide swath of the immune system.

R&D

Jeffrey Meckler having an interview with Jonah Comstock

Reuters Pharma USA 2024 – Jeffrey Meckler

Most of the exciting work being done right now in cancer immunotherapy is centred on highly targeted approaches that aim to activate only the most necessary immune responses to eliminate a

News

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks